PATENT CLAIM ANALYSIS

Application Number: 16297271
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "182000"]

Abstract:
A reagent selected from cholestenoic acid or an inhibitor of an enzyme in the cholestenoic acid biosynthetic or metabolic pathway for use in the treatment of neurodegenerative conditions. in particular, the reagent is a cholestenoic acid of a particular form, such as 3β,7α-dihydroxycholest-5-en-26-oic (3β,7α-diHCA), not previously associated with neural tissue or CSF. Pharmaceutical compositions, methods of treatment or prevention of neurodegenerative conditions as well as diagnostic methods and novel biomarkers form further aspects of the invention.

Claim (Index 18):
A method for diagnosing or predicting a predisposition towards a neurological disorder, which method comprises determining the relative amounts of specific forms of cholestenoic acid and/or a cholestenoic acid precursor present in a biological sample, and relating the result to the presence or absence of or a predisposition towards development of a neurological disorder.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 99.0
- Lexical Diversity: 1.63462
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14770313', '14425548', '13406092', '14976177', '14961823']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7854663678121047
- 35 USC 102 Novelty (BERT): 0.5838277099773878
- Combined Prediction Score: 0.765302502028633
- Mean Citation Score: 379.99412200000006
- Max Citation Score: 900.5553
- Similarity Product: 418.6651144806326

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test